Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Information source: GlaxoSmithKline
Information obtained from ClinicalTrials.gov on 2006-12-04
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Measles; Mumps; Rubella; Chickenpox
Intervention: Measles, Mumps, Rubella and Chickenpox (live vaccine) (Vaccine)
Phase: Phase 3
Status: No longer recruiting
Sponsored by: GlaxoSmithKline
Official(s) and/or principal investigator(s):
Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.
Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals’ Measles-Mumps-Rubella-Varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life
Study design: Interventional, Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety Study
This study included an active control group who received the licensed Priorix (measles, mumps, rubella [MMR] vaccine).
Minimum age: 11 Months.
Maximum age: 13 Months.
- A male or female subject between 11-13 months of age (i. e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination.
- History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial
- Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination
Locations and Contacts
Last updated: July 17, 2006